Affimed (NASDAQ:AFMD) Downgraded by Cantor Fitzgerald to Hold

Affimed (NASDAQ:AFMD) was downgraded by investment analysts at Cantor Fitzgerald from a “strong-buy” rating to a “hold” rating in a report issued on Wednesday,Zacks.com reports.

A number of other research firms have also commented on AFMD. Wells Fargo & Company reissued an “equal weight” rating and issued a $0.10 target price (down previously from $11.00) on shares of Affimed in a report on Tuesday. StockNews.com initiated coverage on Affimed in a report on Sunday, May 11th. They issued a “sell” rating for the company. HC Wainwright lowered Affimed from a “buy” rating to a “neutral” rating in a research report on Wednesday. Leerink Partnrs cut shares of Affimed from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Finally, Leerink Partners reiterated a “market perform” rating and issued a $0.39 price target (down from $5.00) on shares of Affimed in a research note on Tuesday. One analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, Affimed presently has an average rating of “Hold” and a consensus price target of $7.90.

Affimed Stock Performance

Shares of AFMD opened at $0.09 on Wednesday. Affimed has a twelve month low of $0.07 and a twelve month high of $8.95. The firm has a 50 day moving average of $0.75 and a 200 day moving average of $1.44. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.93 and a quick ratio of 1.93.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Affimed stock. Intellectus Partners LLC grew its holdings in shares of Affimed (NASDAQ:AFMD) by 34.0% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 126,414 shares of the biopharmaceutical company’s stock after purchasing an additional 32,053 shares during the quarter. Intellectus Partners LLC owned approximately 0.79% of Affimed worth $150,000 as of its most recent filing with the Securities & Exchange Commission. 30.82% of the stock is owned by institutional investors and hedge funds.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.